What is the purpose of this trial?
This trial is a phase 1/1b study to evaluate the safety, efficacy, and tolerability of APX005M in combination with nivolumab and cabiralizumab.
The phase 1 dose escalation portion of the study will enroll patients with advanced solid tumors melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) in 6 cohorts to determine the recommended phase II dose (RP2D) of APX005M.
The phase 1b dose expansion portion will study the triple drug combination separately in the three disease cohorts: melanoma, NSCLC, and RCC.
Submitted on 3/29/2018; investigational new drug (IND) number is pending and will be added to the record once received.
Yale Cancer Center
Start Date: 06/07/2018
End Date: 01/01/2021
Last Updated: 06/22/2018
Study HIC#: 2000021757